The role of apoptosis in autoimmunity: immtmogen, antigen, and accelerant

Seminars in Nephrology

Volumn 19, Issue 1, 1999, Pages 34-47

  Levine, Jerrold S ^a   Koh, Jason S ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN;

APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; APOPTOSIS; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; SENSITIVITY AND SPECIFICITY;

EID: 0032914025     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Vyse TJ, Todd JA: Genetic analysis of autoimmune disease. Cell 85:311-318, 1996
2. Watanabe-Fukunaga R, Brannan CI, Copeland NG, et al: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317, 1992
3. Koh JS, Levine JS: Apotosis and autoimmunity. Curr Opin Nephrol Hypertens 6:259-266, 1997
4. Majno G, Joris I: Apoptosis, oncosis, and necrosis. Am J Pathol 146:3-15, 1995
5. Raff MC: Social controls on cell survival and cell death. Nature 356:397-400, 1992
6. Lieberthal W, Levine JS: Mechanisms of apoptosis and its potential role in renal tubular epithelial cell injury. Am J Physiol 271 (Renal Fluid Electrolyte Physiol 40):F477-F488, 1996
7. Steller H: Mechanisms and genes of cellular suicide. Science 267:1445-1449, 1995
8. Savill J, Fadok V, Henson P, et al: Phagocyte recognition of cells undergoing apoptosis. Immunol Today 14:131-136, 1993
9. Van Parijs L, Abbas AK: Homeostasis and self-tolerance in the immune system: Turning lymphocytes off. Science 280: 243-248, 1998
10. Theofilopoulos AN, Dixon FJ: Murine models of systemic lupus erythematosus. Adv Immunol 37:269-390, 1985
11. Theofilopoulos AN, Kofler R, Singer PA, et al: Molecular genetics of murine lupus models. Adv Immunol 46:61-109, 1989
12. Kappler JW, Roehm N, Marrack PC: T cell tolerance by clonal elimination in the thymus, Cell 149:273-280, 1987
13. + and abnormal Ipr and gld cell populations. J Exp Med 170:1869-1877, 1989
14. Scott DE, Kisch WJ, Steinberg AD: Studies of T cell deletion and T cell anergy following in vivo administration of SEB to normal and lupus-prone mice. J Immunol 150:664-672, 1993
15. Herren LR, Eisenberg RA, Roper E, et al: Selection of the T cell receptor repertoire in Ipr mice. J Immunol 151:3450-3459, 1993
16. Rathmell JC, Goodnow CC: Effects of the Ipr mutation on elimination and inactivation of self-reactive B cells. J Immunol 153:2831-2842, 1994
17. Rubio CF, Kench J, Russell DM, et al: Analysis of central B cell tolerance in autoimmune-prone MRL///)r mice bearing autoantibody transgenes. J Immunol 157:65-71, 1996
18. Hannum LG, Ni D, Haberman AM, et al: A diseaserelated rheumatoid factor autoantibody is not tolerized in a normal mouse: Implications for the origins of autoantibodies in autoimmune disease. J Exp Med 184:1269-1278, 1996
19. Ray SK, Putterman C, Diamond B: Pathogenic autoantibodies are routinely generated during the response to foreign antigen: A paradigm for autoimmune disease. Proc Natl Acad Sei USA 93:2019-2024, 1996
20. Dalum I, Jensen MR, Hindersson P, et al: Breaking of B cell tolerance toward a highly conserved self protein. J Immunol 157:4796-4804, 1996
21. Mamula MJ, Fatenejed S, Craft J: B cells process and present lupus autoantigens that initiate autoimmune T cell responses. J Immunol 152:1453-1461, 1994
22. James JA, Gross T, Scofield RH, et al: Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J Exp Med 181:453-461, 1995
23. James JA, Harley JB: A model of peptide-induced lupus autoimmune B cell epitope spreading is strain specific and is not H-2 restricted in mice. J Immunol 160:502-508, 1998
24. Topper F, Gordon T, McCIuskey J: Intra- and intermolecular spreading of autoimmunity involving the nuclear selfantigens La (SS-B) and Ro (SS-A). Proc Natl Acad Sei USA 92:875-879, 1995
25. Scofield RH, Henry WE, Kurien BT, et al: Immunization with short peptides from the sequence of the systemic lupus erythematosus-associated 60-kDa Ro autoantigen results in anti-Ro ribonucleoprotein autoimmunity. J Immunol 156:40594066, 1996
26. Keech CL, Gordon TP, McCIuskey J: The immune response to 52-kDa Ro and 60-kDa Ro is linked in experimental autoimmunity. J Immunol 157:3694-3699, 1996
27. Reynolds P, Gordon TP, Purcell AW, et al: Hierarchical self-tolerance to T cell determinants within the ubiquitous nuclear self-antigen La (SS-B) permits induction of systemic autoimmunity in normal mice. J Exp Med 184:1857-1870, 1996
28. Lou Y-H, McElveen MF, Garza KM, et al: Rapid induction of autoantibodies by endogenous ovarian antigens and activated T cells: Implication in autoimmune disease pathogenesis and B cell tolerance. J Immunol 156:3535-3540, 1996
29. Rauch J, Subang R, Koh JS, et al: Induction of antiphospholipid antibodies by /32-glycoprotein I bound to apoptotic thymocytes. Lupus 7:66, 1998 (abstr) (Suppl 1)
30. Kouts S, Wang M-X, Adelstein S, et al: Immunization of a rabbit with β2-glycoprotein I induces charge-dependent cross-reactive antibodies that bind anionic phospholipids and have similar reactivity as autoimmune anti-phospholipid antibodies. J Immunol 155:958-966, 1995
31. Filion MC, Bradley AJ, Devine DV, et al: Autoreactive T cells in healthy individuals show tolerance in vitro with characteristics similar to but distinct from clonal anergy. Eur J Immunol 25:3132-3127, 1995
32. Singer GG, Abbas AK: The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1:365-371, 1994
33. Mogil RJ, Radvanyi L, Gonzalez-Quintial R, et al: Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. Int Immunol 7:1451-1458, 1994
34. Rathmell JC, Townsend SE, Xu JC, et al: Expansion or elimination of B cells in vivo: Dual Roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 87:319-329, 1996
35. Rüben P, Barbas SM, Sandoval L, et al: Repertoire cloning of lupus anti-DNA autoantibodies. J Clin Invest 98: 2827-2837, 1996
36. Nagata S: Apoptosis by death factor. Cell 88:355-365, 1997
37. Mountz JD, Zhou T, Su X, et al: The role of programmed cell death as an emerging new concept for the pathogenesis of autoimmune diseases. Clin Immunol Immunopath 80:S2-S14, 1996 (suppl)
38. Cohen PL, Eisenberg RA: Ipr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Ann Rev Immunol 9:243-269, 1991
39. Zhou T, Edwards CK III, Yang P, et al: Greatly accerlerated lymphadenopathy and autoimmune disease in Ipr lacking tumor necrosis factor receptor I. J Immunol 156:2661-2665, 1996
40. Rieux-Laucat F, Le Deist F, Hivroz C, et al: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347-1349, 1995
41. Drappa J, Vaishnaw AK, Sullivan KE, et al: Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 335:1643-1649, 1996
42. Wu, J, Wilson J, He, et al: Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 98:1107-1113, 1996
43. Suda T, Tanaka M, Miwa K, et al: Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand. J Immunol 157: 3918-1924, 1996
44. Miethke T, Vabulas R, Bittlingmaier R, et al: Mechanisms of peripheral T cell deletion: Anergized T cells are Fas resistant but undergo proliferation-associated apoptosis. Eur J Immunol 26:1459-1467, 1996
45. Tucek-Szabo, CL, Andjelic S, Lacy E, et al: Surface T cell Fas receptor/CD95 Regulation, in vivo activation, and apoptosis: Activation-induced death can occur without Fas receptor. J Immunol 156:192-200, 1996
46. Zheng L, Fisher G, Miller RE, et al: Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377:348-351, 1995
47. Emlen W, Niebur J, Kadera R: Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 152:3685-3692, 1994
48. Lorenz H-M, Grünke M, Hieronymus T, et al: In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum 40:306-317, 1997
49. Perniok A, Wedekind F, Herrmann M, et al: High levels of circulating early apoptotic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus 7:113-118, 1998
50. Georgescu L, Vakkalanka RD, Elkon KB, et al: Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest 100:2622-2633, 1997
51. Zhao Z-S, Granucci F, Yeh L, et al: Molecular mimicry by herpes simplex virus-type 1: Autoimmune disease after viral infection. Science 279:1344-1347, 1998
52. Enari M, Sakahira H, Yokayama H, et al: A caspaseactivated endonuclease that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391:43-50, 1998
53. Burlingame RW, Boey ML, Starkebaum G, et al: The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 94: 184-192, 1994
54. Amoura A, Chabre H, Koutouzov S, et al: Nucleosomerestricted antibodies are detected before anti-dsDNA and/or antihostone antibodies in serum of MRL-Mp Ipr/lpr and +/+ mice, and are present in kidney eluates of lupus mice with proteinuria. Arthritis Rheum 37:1684-1688, 1994
55. Burlingame RW, Rubin RL, Balderas RS, et al: Genesis and evolution of antichromatin autoantibodies in murine lupus implicates T-dependent immunization with self antigen. J Clin Invest 91:1687-1696, 1993
56. Mohan C, Adams S, Stanik V, et al: Nucleosome: A major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 177:1367-1381, 1993
57. Desai-Mehta A, Mao C, Rajagopalan S, et al: Structure and specificity of T cell receptors expressed by potentially anti-DNA autoantibody-inducing T cells in human lupus. J Clin Invest 95:531-541, 1995
58. Kaliyaperumal A, Mohan C, Wu W, et al: Nucleosomal peptide epitopes for nephritis-inducing T helper cells of murine lupus. J Exp Med 183:2459-2469, 1996
59. Mohan C, Alas E, Morel L, et al: Genetic dissection of SLE pathogenesis: Slel on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes. J Clin Invest 101:1362-1372, 1998
60. Casciola-Rosen LA, Anhalt G, Rosen A: Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 179:1317-1330, 1994
61. Casciola-Rosen LA, Anhalt G, Rosen A: DNA-dependent protein kinase is one of a subset of autoantigens specifically cleaved early during apoptosis. J Exp Med 182:16251634, 1995
62. Casciola-Rosen LA, Rosen A, Petri M, et al: Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: Implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sei USA 93:1624-1629, 1996
63. Price BE, Rauch J, Shia MA, et al: Antiphospholipid autoantibodies bind to apoptotic, but not nonapoptotic, thymocytes in a /32-glycoprotein I-dependent manner. J Immunol 157:2201-2208, 1996
64. Gilligan HM, Bredy B, Brady HM, et al: Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. J Exp Med 184:2231-2241, 1996
65. Casciola-Rosen L, Nicholson DW, Chong T, et al: Apopain/CPP32 cleaves proteins that are essential for cellular repair: A fundamental principle of apoptotic death. J Exp Med 183:1957-1964, 1996
66. Casiano CA, Martin SJ, Green DR, et al: Selective cleavage of nuclear autoantigens during CD95 (Fas/APO-1)-mediated T cell apoptosis. J Exp Med 184:765-770, 1996
67. Madaio MP, Fabbi M, Tiso M, et al: Spontaneously produced anti-DNA/DNase I autoantibodies modulate nuclear apoptosis in living cells. Eur J Immunol 26:3035-3041, 1996
68. Lazebnik YA, Takahashi A, Moir RD, et al: Studies of the lamin protease reveal multiple parallel biochemical pathways during apoptotic execution. Proc Natl Acad Sei USA 92:9042-9046, 1955
69. Wasicek CA, Reichlin M: Clinical and serologie differences between systemic lupus erythematosus patients with antibodies to Ro versus patients with antibodies to Ro and La. J Clin Invest 69:835-843, 1982
70. Schur PH, Moroz LA, Kunkel HG: Precipitating antibodies to ribosomes in the serum of patients with systemic lupus erythematosus. Immunochemistry 4:447-452, 1967
71. Siegert CEH, Daha MR, Tseng, CMES, et al: Predictive value of IgG autoantibodies agaisnt Clq for nephritis in systemic lupus erythematosus. Ann Rheum Dis 52:851-856, 1993
72. Foster MH, Sabbaga J, Line SRP, et al: Molecular analysis of spontaneous nephrotropic anti-lamin antibodies in an autoimmune MRL-lpr/lpr mouse. J Immunol 151:814-824, 1993
73. Atta MS, Powell RJ, Hopkinson ND, et al: Human anti-fibronectin antibodies in systemic lupus erythematosus: Occurrence and antigenic specificity. Clin Exp Immunol 96:20-25, 1994
74. Moreland LW, Gay RE, Gay S: Collagen autoantibodies in patients with vasculitis and systemic lupus erythematosus. Clin Immunol Immunopath 60:412-418, 1991
75. Stetler DA, Cavallo T: Anti-RNA polymerase I antiboides: Potential role in the induction and progression of murine lupus nephritis. J Immunol 138:2119-2123, 1987
76. Lefkowith JB, Gilkeson GS: Nephritogenic autoantibodies in lupus: Current concepts and continuing controversies. Arthritis Rheum 39:894-903, 1996
77. Hecht B, Siegel N, Adler M, et al: Prognostic indices in lupus nephritis. Medicine (Baltimore) 55:163-181, 1976
78. Yamada A, Miyakawa Y, Kosaka K: Entrapment of anti-DNA antibodies in the kidney of patients with lupus erythematosus. Kidney Int 22:671-676, 1982
79. Ravirajan CT, Rahman MA, Papadaki L, et al: Genetic, structural and functional properties of an IgG DNA-binding monoclonal antibody from a lupus patient with nephritis. Eur J Immunol 28:339-350, 1998
80. van Bruggen MCJ, Walgreen B, Rijke TPM, et al: Antigen specificity of anti-nuclear antibodies complexed to nucleosomes determines glomerular basement membrane binding in vivo. Eur J Immunol 27:1564-1569, 1997
81. Termaat RM, Brinkman V, Van Compel F, et al: AntiDNA antibodies can bind to the glomerulus via two distinct mechanisms. Kidney Int 42:1363-1371, 1992
82. Morioka T, Woitas R, Fujigaki Y, et al: Histone mediates glomerular deposition of small size DNA anti-DNA complex. Kidney Int 45:991-997, 1994
83. Kramers C, Hylkema MN, van Bruggen MC, et al: Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest 94:568-577, 1994
84. Pereira LF, Marco FM, Boimorto R, et al: Histones interact with anionic phospholipids with high avidity: Its relevance for the binding of histone-antihistone immune complexes. Clin Exp Immunol 97:175-180, 1994
85. Ohnishi K, Ebling FM, Mitchell B, et al: Comparison of pathogenic and non-pathogenic murine antibodies to DNA: Comparison of binding and structural characteristics. Int Immunol 6:817-830, 1994
86. Runmore PM, Steinman CR: Endogenous circulating DNA in systemic lupus erythematosus: Occurrence as multimeric complexes bound to histone. J Clin Invest 86:69-74, 1990
87. Tax WJM, Kramers C, van Bruggen MCJ, et al: Apoptosis, nucleosomes, and nephritis in systemic lupus erythematosus. Kidney Int 48:666-673, 1995
88. Albert ML, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86-89, 1998
89. Bellone M, lezzi G, Rovere P, et al: Processing of engulfed apoptotic bodies yields T cell epitopes. J Immunol 159:5391-5399, 1997
90. Kotzin BL: Systemic lupus erythematosus. Cell 85:303306, 1996
91. Mills JA: Systemic lupus erythematosus. N Engl J Med 330:1871-1879, 1994
92. Jevnikar AM, Grusby MJ, Glimcher LH: Prevention of nephritis in major histocompatibility complex class H-deficient MRL-/pr mice. J Exp Med 179:1137-1143, 1994
93. Ohteki T, Iwamoto M, Izui S, et al: Reduced development of CD4~CD8~B220+ T cells but normal autoantibody production in Ipr/lpr mice lacking major histocompatibility complex class I molecules. Eur J Immunol 25:37-41, 1995
94. Wofsy D, Seamen WE: Successful treatment of autoimmunity in NZB/NZW Fl mice with monoclonal antibody to L3T4. J Exp Med 161:378-391, 1985
95. Santoro TJ, Portanova JP, Kotzin BL: The contribution of L3T4+ T cells to lymphoproliferation and autoantibody production in MRL-lpr/lpr mice. J Exp Med 167:1713-1718, 1988
96. Koh D-R, Ho A, Rahemtulla A, et al: Murine lupus in MRUIpr mice lacking CD4 or CDS T cells. Eur J Immunol 25:2558-2562, 1995
97. Chen S-Y, Takeoka Y, Ansari AA, et al: The natural history of disease expression in CD4 and CDS gene-deleted New Zealand black (NZB) mice. J Immunol 157:2676-2684, 1994
98. Giese T, Davidson WF: Chronic treatment of C3H-tpr/ Ipr and C3H-gId/gld mice with anti-CD8 monoclonal antibody prevents the accumulation of double negative T cells but not autoantibody production. J Immunol 152:2000-2010, 1994
99. Satoh M, Ajmani AK, Stojanov L, et al: Autoantibodies that stabilize the molecular interaction of Ku antigen with DNA-dependent protein kinase catalytic subunit. Clin Exp Immunol 105:460-467, 1996
100. Haneji N, Nakamura T, Takio K, et al: Identification of a-fodrin as a candidate autoantigen in primary Sjögren's syndrome. Science 276:604-607, 1997